Showing 121-130 of 1039 results for "".
DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markePhysician Spotlight: J. Matthew Knight, MD, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-j-matthew-knight-md-faad/20561/Dermatologists must act now to extinguish burnout or risk dire consequences.Physician Spotlight: George J. Hruza, MD, MBA, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-george-j-hruza-md-mba-faad/23062/MIPS: The Secret to His Success
https://practicaldermatology.com/topics/practice-management/mips-the-secret-to-his-success/23117/Windsor Dermatology’s Dr. David Nieves shares his successful MIPS action plan.Meeting the Needs of Today's Injectables Market
https://practicaldermatology.com/videos/c-suite-chats/meeting-needs-todays-injectables-market/26926/David Moatazedi, president and CEO of Evolus, talks about trends in the injectables market and the needs of younger generations.Improving Treatment Capabilities for Vitiligo
https://practicaldermatology.com/videos/c-suite-chats/improving-treatment-capabilities-for-vitiligo/29745/David Domzalski, CEO and President of Vyne Therapeutics, discusses what makes vitiligo difficult to treat and how his company is working to address those challenges.Clinical Conversations: Discover Dr J Scott Boswell’s Perspective on Redefining PN and AD Through a Neuroimmune Lens
https://practicaldermatology.com/videos/nemluvio-peer-network/clinical-conversations-discover-dr-j-scott-boswells-perspective-on-redefining-pn-and-ad-through-a-neuroimmune-lens/56421/In this Clinical Conversations newsletter, Dr Scott Boswell shares how reframing prurigo nodularis (PN) and atopic dermatitis (AD) as neuroimmune-driven conditions has shaped his clinical philosophy. He shares his 3‑step approach to patient communication, highlights real‑world treatment journeys inA Meeting for Treating the Whole Person
https://practicaldermatology.com/conferences/noah-worcester/a-meeting-for-treating-the-whole-person/57065/Stan Tolkachjov, MD, Scientific Program Co-chair for the Noah Worcester Dermatological Society’s 2026 Annual Meeting, explains what he and Co-chair David Wetter, MD, sought to accomplish with this year’s presentations.Evaluating GEP Test Options
https://practicaldermatology.com/programs/practical-dermatology/evaluating-gep-test-options/35600/David Cotter, MD, a board-certified dermatologist, discusses what he looks for in a gene expression profile (GEP) test, including the types of clinical evidence that are most important.Pearls for Monitoring and Managing Itch: An Expert Panel
https://practicaldermatology.com/topics/atopic-dermatitis/pearls-for-monitoring-and-managing-itch-an-expert-panel/27172/A three-person panel covered the topic of itch recently at The Dermatology Education Foundation’s DEF Essential Resource Meeting 2024 (DERM2024) NP/PA CME Conference in Las Vegas, Nevada, with David Cohen, MD, MPH, leading “How to Avoid Doctor Strange: Pearls for Monitoring and Managing Itch.” Dr. C